Objective: Using systematic review methodology, we endeavored to answer the following questions concerning the treatment of osteochondral pathology: (1) Data Sources: A systematic literature search was performed of the OVID, EMBASE, and Evidence Based Medicine Reviews databases to identify all studies published up to October 2012 that assessed clinical outcomes of the use of PRP for the treatment of chondral and osteochondral pathology, excluding those including concomitant management of acute fractures or ligament reconstruction.
INTRODUCTION
Articular cartilage pathology represents a spectrum of potentially debilitating conditions that can have substantial impact on patient well-being, with symptoms including persistent joint pain and decreased function. Both chondral and osteochondral lesions of a number of synovial joints are being diagnosed with increasing frequency. 1, 2 The natural history of these lesions often includes progression to symptomatic osteoarthritis and functional impairment in otherwise young and active patients. 3, 4 Several treatment modalities are available, including microfracture, autologous chondrocyte transplantation, and autograft and allograft osteochondral transplantation. 5 However, the reported results with these procedures have been variable and are not guaranteed to prevent symptomatic degenerative disease at long-term follow-up. 6 Articular cartilage has limited inherent healing capacity due to its avascular and alymphatic nature. [7] [8] [9] In isolation from the systemic circulation, the normal inflammatory and reparative processes are unable to assist with repair of injured cartilage in a synovial joint, and adjacent healthy chondrocytes are prevented from migrating to the injured area by the extracellular matrix. 10 Although injuries that penetrate subchondral bone can stimulate underlying marrow cells to produce a systemic response to generate new tissue, the result is the formation of biomechanically inferior fibrocartilage consisting primarily of type 1 collagen. 11, 12 Autologous platelet-rich plasma (PRP) has been reported to release a number of cytokines and growth factors that stimulate the healing of bone and soft tissue and has been advocated in the treatment of a wide range of musculoskeletal pathologies. [13] [14] [15] [16] [17] Chondrocytes stimulated with PRP in vitro have been shown to increase their synthesis of proteoglycans and collagen, 18 with the repair tissue generated after PRP treatment demonstrating similar histological and biomechanical characteristics to normal hyaline cartilage. 13, 19, 20 Recently, PRP has been investigated as a biologic solution in the treatment of osteochondral pathology and osteoarthritis. Results from animal studies have identified the potential utility of PRP, both in isolation and as an adjunct to surgical procedures, to restore normal hyaline cartilage in articular injuries. 17, 21, 22 However, despite the theoretical basis for the use of PRP in the treatment of osteochondral pathology, ongoing controversy remains regarding its clinical efficacy in vivo.
The purpose of the present study was to systematically review the published literature to answer the following questions: (1) 
MATERIALS AND METHODS

Eligibility Criteria
Original studies investigating the use of autologous PRP in human subjects for the treatment of chondral or osteochondral lesions were considered eligible for inclusion. Articular cartilage pathology of any synovial joint was considered eligible for inclusion, including both traumatic osteochondral defects and posttraumatic or idiopathic degenerative osteoarthritis. Studies reporting clinical results at any time interval after treatment were included. Any studies that investigated acute or nonunited intra-articular fractures without specific articular chondral defects were excluded, as were those that included patients undergoing concomitant ligament reconstruction. Case reports, defined as reports concerning the treatment of less than 5 patients, and review articles, editorials, letters to the editor, and textbook chapters were deemed ineligible for inclusion. Only studies with full-text reports available in English were included.
Information Sources and Search
Separate electronic searches of each of the following databases were performed: MEDLINE, EMBASE, and Evidence Based Medicine Reviews-Cochrane Central Register of Controlled Trials. All records indexed up to and including October 11, 2012, were included. The search was performed using a combination of MeSH headings and textwords to capture any records addressing "cartilage" or "joint disease/ injuries" and "platelet-rich plasma/PRP." The full search strings can be found in the Appendix. The results of the FIGURE. Flow diagram summarizing the literature search, screening, and review. MEDLINE and EMBASE searches were then screened using meta-data fields to include only those addressing clinical investigations in human subjects. The specific filter criteria can be found in the Appendix. This process excluded 513 records, with 167 remaining for review ( Figure) . These records were extracted to reference manager software and manually searched for duplicate entries. After removing 42 duplicate entries, 125 records remained for review. 
Study Selection
The remaining citation records were extracted to spreadsheet software for further assessment and tracking, which was performed in duplicate by 2 of the authors (A.P.D. and M.G.Z.). Any discrepancies were resolved by consensus discussion among all the study authors. The titles and abstracts of all records were reviewed, and any deemed ineligible based on our previously described criteria were excluded. Full-text manuscripts for any records deemed to be of unknown relevance or likely relevant were obtained and reviewed. Any studies deemed ineligible after full-text review were also excluded. In total, 114 records were excluded through this process for the following reasons: no available English full-text reports (5 records), published editorials, commentaries, or short notes (6 records), letters to the editor (3 records), review articles (30 records), technique articles (1 record), textbook chapters (5 records), and studies of nonapplicable pathology (64 records). The reference lists of the remaining 11 study reports were reviewed for any potentially relevant studies not identified through our search. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] No further reports were found that were deemed potentially or likely relevant. Two records were reports on the same investigation at different time intervals. 24, 25 These were treated as a single study for the purposes of our review, thus leaving 10 studies in our final synthesis (Table 1) .
Data Collection
The full-text reports of the 10 studies included in the final review were assessed and the following data were extracted to spreadsheet software: (1) study details including authors, year of publication, and study design; (2) study population including the number of patients and cartilage pathology studied; (3) preintervention assessment including clinical and pain scores and radiographic findings; (4) intervention details including PRP source, collection, preparation and delivery methods, and concurrently performed adjunct procedures; (5) comparison group details including study population and demographics and control intervention; and (6) postintervention data including follow-up times, clinical outcomes, and complications or adverse events.
Study Designs and Study Quality
Of the 10 studies included in the final review, there were 2 randomized controlled trials, 26 ,32 1 prospective comparative study, 27 1 retrospective comparative study, 29 and 6 case series reports. 23, 24, 28, 30, 31, 33 The risk of bias in the 3 prospective studies was assessed using the Cochrane Collaboration's tool as reported by Higgins et al. 34 Either unclear or high risk of bias was found for all assessed categories in all 3 
studies, with the exception of a low risk of attrition and baseline comparability in the nonrandomized comparative study reported by Mei-Dan et al 27 ( Table 2) .
RESULTS
Pathology
The majority of studies (7 of 10) investigated the use of PRP in patients with symptomatic osteoarthritis, with all but one study investigating primary or exclusively degenerative pathology (Table 1) . These included 6 studies treating patients with osteoarthritis of the knee 24,26,28-30,32,33 and 1 study treating patients with osteoarthritis of the hip, 30 encompassing a total of 570 joints (530 knees and 40 hips) in 546 patients.
One study investigated the use of PRP in 52 patients with full-thickness chondral lesions of any articular surface in the knee, 31 with defect sizes ranging between 15 and 50 mm 2 . The defects were reported to be posttraumatic in 5 (10%) patients and degenerative in 47 (90%) patients. One study reported the use of PRP in 5 patients with focal degenerative full-thickness chondral lesions of the patella, 23 ranging in size from 1 to 3 cm 2 . Finally, 1 study reported the use of PRP in 15 patients with osteochondral lesions of the talus not associated with radiographic evidence of osteoarthritis at a mean of 7.2 years after the injury 27 and who had previously failed nonoperative management.
Preparation and Delivery Techniques
Multiple PRP preparation techniques were reported, with only 2 methods used in more than 1 study (Table 3) . In 9 studies, PRP was produced from between 18 and 150 mL of whole blood drawn into collection tubes from the patient, 23, 24, [26] [27] [28] [29] [30] 32, 33 whereas in 1 study, it was obtained via plateletpheresis to a defined (but unreported) volume using an automated cell sorting machine. 31 Of the studies that used collection tubes, between 1 and 3 centrifugation steps were performed to obtain PRP volumes ranging from 2 to 20 mL. Actual platelet concentration assay results were reported for 4 studies. 24, 26, 31, 32 The PRP was activated through the addition of 10% calcium chloride in 6 studies, 24, 26, 27, 29, 30, 33 whereas unactivated PRP was used in the remaining 4 investigations.
Eight studies investigated direct injection of between 2 and 8 mL of PRP into the affected joint. 24, [26] [27] [28] [29] [30] 32, 33 Three injections were performed in all cases, at intervals ranging from 1 to 3 weeks. The remaining 2 studies investigated the use of PRP as an adjunct to drilling of focal chondral defects of the knee. In 1 study, gelled PRP solution was added to and contained within the defect by a collagen membrane sutured to the margin. 23 In the second study, the PRP was first soaked into a polyglycolic acid-hyaluronan scaffold that was subsequently placed into the defect and retained with either absorbable pins or gelled PRP fibrin-like adhesive. 31 
Outcome Measures and Follow-up Times
A range of clinical, radiographic, and pathological assessment methods were reported. All studies used 1 or more primarily patient-centered outcome scores to assess the effectiveness of PRP in the treatment of osteochondral pathology. The Western Ontario and McMaster Universities' Arthritis Index (WOMAC) was the most commonly reported clinical score used in 3 studies. A visual analogue scale (VAS) was the most commonly used assessment of pain reported in 4 studies. No other clinical outcome measure was used in more than 2 studies. Six studies reported outcomes at final follow-up times of 6 months or less, 26, 27, 29, 30, 32, 33 with 1 study reporting outcomes at 5 weeks posttreatment only. 29 No study reported outcomes more than 24 months after treatment.
Radiographic outcomes were reported for 3 studies, with 1 using ultrasound and 2 performing magnetic resonance imaging assessment of cartilage thickness at the 6-month to 24-month follow-up. 23, 28, 31 Finally, tissue samples were obtained in 1 study in a subset of patients at the 9-month follow-up for microscopic evaluation. 31 Of the 4 studies that included a comparison group, 26, 27, 30, 32 3 intra-articular injections of hyaluronic acid were given to all control patients at the same time intervals as the study group PRP injections. Only clinical results were assessed in these 4 studies, with final follow-up times of 6 months in 3 studies and 5 weeks in the fourth.
Clinical Results
All the assessed studies assessed outcomes using jointspecific clinical scores, general health assessment scores, pain scales, or a combination of these measures. Significant improvements in WOMAC; Lequesne, Ankle and Hindfoot; Knee Injury and Osteoarthritis Outcome; and International Knee Documentation Committee (IKDC) scores were consistently reported up to 6 months after intra-articular PRP injection compared with both hyaluronic acid injection and/or preintervention values for both degenerative osteoarthritis and focal chondral lesions (Table 4 ). Filardo et al 24 reported significantly improved IKDC scores up to 24 months after intraarticular knee injection of PRP for knee osteoarthritis, although the authors noted that the scores peaked at the 6-month follow-up, with subsequent significant decline. No studies treating knee osteoarthritis or focal chondral lesions with PRP failed to show significant improvements and/or differences in joint-specific clinical scores, although Sanchez et al 29 did not report comparative data between PRP and hyaluronic acid groups.
Four studies investigating knee osteoarthritis reported significantly improved patient-reported health status scores measured using either Short Form 36 (SF-36) or EuroQol Visual Analogue Scale (EQ VAS) instruments after PRP injection (Table 5) . 24, 26, 32, 33 These differences were maintained up to the 6-month final follow-up in 3 studies, 26, 32, 33 with significantly better scores reported in patients treated with PRP compared with hyaluronic acid in 2 reports. 26, 32 Filardo et al 24 reported significantly improved EQ VAS scores at a final follow-up of 24 months compared with baseline, although the authors again noted that the scores peaked at the 6-month follow-up and subsequently declined.
With regard to pain scores, 6 studies treating both degenerative osteoarthritis and focal chondral lesions consistently demonstrated improved results when compared with baseline at follow-up times up to 12 months for both denegerative osteoarthritis and focal chondral lesions (Table 6) . 23, 27, 28, 30, 32, 33 Dhollander et al 23 demonstrated improved pain scores up to 24 months after microfracture of patellar lesions supplemented with local application of PRP, although this study included only 5 patients and no statistical comparison was performed. Spakova et al 32 reported significantly lower pain scores at final follow-up in patients with knee osteoarthritis treated with PRP compared with hyaluronic acid. Sanchez et al reported significantly lower pain scores at 6-month follow-up in patients with hip osteoarthritis treated with PRP injections, although the presentation of scores was limited to box plots only, without the inclusion of actual numeric mean scores or ranges. Finally, Mei-Dan failed to demonstrate a significant difference between PRP and hyaluronic acid injections in patients with osteochondral lesions of the talus despite considerably different mean pain scores at final follow-up, although this may be because of a lack of adequate powering of the study, with only 15 patients per treatment group (mean VAS scores at final follow-up of 0.9 vs 3.1; P . 0.05) ( Table 6 ).
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DISCUSSION
The past several years have been marked by a rapid proliferation of interest in the use of PRP for the treatment of a wide range of musculoskeletal pathology, 38, 39 ranging from treatment of tendiopathy and ligament injuries, 40 to use as an adjunct to bone grafting in procedures such as spinal fusion.
This growing interest in the use of PRP has been met with the development and marketing of several commercial PRP preparation kits, which may further promote wider use of this technique. Recent animal studies have suggested that PRP may mitigate some of the difficulties of healing injuries within the intra-articular milieu, and some authors have advocated the use of this preparation for the treatment of chondral and osteochondral injuries. 17, 21, 22 With this in mind, we asked what evidence has been published concerning the use of PRP for the treatment of chondral pathology in humans.
We acknowledge a number of limitations of the present study. First, the use of PRP for the treatment of human focal chondral defects is a relatively recent development, with only 1 study identified that was published before 2012. Given this, and the expanding interest in its use, it is possible that there are a number of studies that are either in progress or recently completed but not yet published that were not captured by our review. Second, by excluding reports published in languages other than English, it is possible that we have failed to include the results of studies that were otherwise relevant to the questions asked. Third, our findings may be skewed by publication bias because there is a well-described prejudice toward the publication of positive or favorable findings, 41 and our review was not able to capture any studies that failed to demonstrate clinical benefit for the use of PRP and remain unreported. Finally, the generalizability of our findings is limited by the weakness of the studies reviewed, most notably the heterogeneity in PRP preparation and delivery techniques, short-term clinical follow-up, and high risk of bias in prospective studies. Nevertheless, we believe that the methodology used accurately presents the current state of published evidence concerning the use of PRP for the treatment of chondral pathology.
Although the present review focused on the spectrum of chondral pathology, the majority of the evidence published to date specifically addresses the use of PRP for the treatment of degenerative osteoarthritis. Six studies limited enrollment to this population, 24, 26, 28, 29, 32, 33 whereas a seventh treated osteoarthritis of the hip. 30 The results of the present review do suggest that a series of intra-articular injections of PRP may provide some short-term clinical benefit in symptomatic arthritis of the knee as demonstrated by improved clinical scores and decreased pain at 6-month follow-up. However, studies with 2-year follow-up suggest that although improvements may be maintained at 2 years, there is a significant decline in outcome scores beyond 6 months.
Only 3 studies treated isolated osteochondral lesions of the knee or talus lesions with PRP, 23, 27, 31 although 47 of the 52 lesions in one of these studies were reported to be degenerative. Furthermore, in 2 of these 3 studies, PRP was used as an adjunct to surgical procedures without a surgery-only comparison group, limiting any assessment of the clinical benefit of its benefit. 23, 31 As a result, although there is some suggestion that the use of PRP may provide some short-term benefit in the treatment of focal chondral lesions, further research is required. Overall, there is limited evidence to date supporting the use of PRP, whether alone or as an adjunct to surgical treatment, in the management of chondral or osteochondral defects.
Three comparison studies have demonstrated superior clinical results treating either knee osteoarthritis or osteochondral lesions of the talus with PRP in comparison with hyaluronic acid. 26, 27, 32 Interestingly, recent systematic reviews conducted by Rutjes et al 42 and Loveday et al 43 revealed no clinically relevant benefit through the use of HA in the management of either of these pathologies. Furthermore, given the unclear or high risk of multiple types of bias identified in all the comparative studies included in the present review, these findings should be interpreted with caution-once more, further welldesigned comparative trials are required.
In summary, the majority of evidence regarding the use of injected PRP relates to osteoarthritis of the knee. These data suggest that the benefits of reduced pain and improved clinical scores begin to lessen after 6 months. At the present time, there is no conclusive or high-quality evidence available to support the use of PRP for either traumatic or degenerative chondral pathology or to suggest any lasting clinical benefit to its use. Further studies are needed and should focus on highquality randomized controlled trials, both of PRP injections compared with placebo and surgical treatment supplemented by PRP compared with operative management alone.
